BioVaxys Technology (TSE:BIOV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioVaxys Technology Corp. has announced the engagement of Dr. Rajkannan Rajagopalan as an advisor to enhance the development and production of the company’s innovative DPX™ vaccine formulations. Dr. Rajagopalan’s extensive experience in nanoparticle formulation for various diseases brings a wealth of knowledge to the company’s vaccine programs, including a peanut allergy vaccine and ongoing oncology and infectious disease studies. His expertise is expected to bolster BioVaxys’s capabilities in creating a thermostable vaccine platform and assisting in the establishment of a non-GLP clinical supply facility.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges